ArticleLasers in medical science2024
Ablative radiofrequency microplasma for lateral dermatochalasis-indications and treatment recommendations.
Article in Lasers in medical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To determine in which cases ablative radiofrequency microplasma is preferred for the treatment of lateral dermatochalasis over a surgical approach as well as discussing each method's benefits and limitations. Twenty-one patients underwent 3 interventions of plasma exeresis. Photographic and RCM images were acquired at baseline and 4 weeks after final plasma exeresis. The eyes were categorized into 3 groups based on the dermatochalasis severity (1- mild, 2- moderate, 3- severe). Additionally, a further division was conducted to assess the degree of enhancement observed after the treatment (1- slight improvement, 2- moderate improvement, 3- significant improvement). The classifications and assessments were performed by was graded by two trained dermatologists as blinded observers. A total of 21 eyes with a mean age of 54 years (range45-67 years) and 100% females were included in this study. The severity of dermatochalasis directly affects the clinical improvement (P=0.039) and the higher the severity, the more the improvement (R = -0.62). Noninvasive ablative microplasma may offer safe and effective therapy for upper eyelid dermatochalasis and can even be performed in patients at surgical risk. However, it may be suitable for grades 0 and 1 of DC. For more advanced grades a surgical solution achieves better results for the treatment of dermatochalasis of the upper eyelid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.